EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Updated Phase 3 ARDS Results Continue to Show Mortality Benefit On February 24, 2026, Edesa Biotech, Inc. (NASDAQ:EDSA) announced additional Pha ...
Of course, all of this now highly probable growth is underpinned by clinical data that we have already generated across our four Phase 3s as well as data that we continue to generate, and a commercial ...
Abstract: A three-phase, four-arm cascaded H-bridge (CHB) topology is proposed to reduce the power-electronic hardware required by conventional three-phase, direct-hanging flexible arc-suppression ...
Q4 2025 Earnings Call February 19, 2026 10:30 AM ESTCompany ParticipantsTommy HortonRobert Martin Friedland - Founder ...
Abstract: The three-phase dual-active-bridge converter exhibits an inherent fault-tolerant capability for addressing open-circuit failures (OCFs). The frozen leg method is a notable fault-tolerant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results